Interleukin-1
Interleukin-1 - Related Videos
03:33
Evaluating the Effects of Fecal Microbiota Transplantation in an Interleukin-10 Deficient Mouse
0 Views •
2025
This video demonstrates a procedure of fecal microbiota transplantation in an interleukin-10 deficient mouse with colon inflammation. Colonized fecal microbes in the gut release secondary metabolites, eliciting anti-inflammatory cytokine release and reducing colon inflammation.
08:43
Microinjection of Interleukin-6 into the Bloodstream of TSC Zebrafish Larvae to Study Neuropsychiatric Disorder-Like Behaviors
0 Views •
2026
To model how inflammatory signals influence neurodevelopment in genetically susceptible organisms, we present a protocol for microinjecting IL-6 into the duct of Cuvier (common cardinal vein) of zebrafish larvae, enabling controlled induction of inflammation and assessment of its developmental impact in the context of tuberous sclerosis complex (TSC).
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
0 Views •
Cited by 6 •
2022
The interaction of genetic susceptibility, mucosal immunity, and intestinal microecological environment is involved in the pathogenesis of inflammatory bowel disease (IBD). In this study, we applied fecal microbiota transplantation to IL-10 deficient mice and investigated its impact on colonic inflammation and heart function.
10:07
Growing Magnetotactic Bacteria of the Genus Magnetospirillum: Strains MSR-1, AMB-1 and MS-1
0 Views •
Cited by 17 •
2018
We present a procedure for growing several strains of Magnetospirillum in two different types of growth media. Magnetospirillum gryphiswaldense strain MSR-1 is grown in both liquid and O2 concentration gradient semi-solid media while M. magneticum strain AMB-1 and M. magnetotacticum strain MS-1 are grown in liquid medium.
11:22
Cardiac Muscle-cell Based Actuator and Self-stabilizing Biorobot - PART 1
0 Views •
Cited by 3 •
2017
In this two-part study, a biological actuator was developed using highly flexible polydimethylsiloxane (PDMS) cantilevers and living muscle cells (cardiomyocytes), and characterized. The biological actuator was incorporated with a base made of modified PDMS materials to build a self-stabilizing, swimming biorobot.
FAQs
After IL-1 binds its receptor, the signal is transmitted through NF-κB and MAPK pathways. These signaling systems activate inflammatory gene expression rather than producing only a short-lived cellular response. The resulting transcriptional changes help explain how receptor engagement leads to coordinated effects such as leukocyte recruitment, fever, and acute-phase responses.
IL-1β commonly depends on inflammasome activation and caspase-1 processing before it can be released. This adds a regulated step between inflammatory stimulation and cytokine availability. Consequently, studying IL-1β requires attention not only to receptor signaling but also to the upstream processes that control its maturation and release during infection or tissue damage.
IL-1α and IL-1β belong to the same cytokine family and signal through the IL-1 receptor, so both can contribute to inflammatory gene activation. A key distinction is that IL-1β commonly requires inflammasome activation and caspase-1 processing for release. This difference helps researchers separate cytokine production and processing from the shared downstream receptor response.
Researchers examine IL-1 to connect infection or tissue damage with the broader innate immune response. Its downstream effects provide a framework for studying inflammatory gene activation, fever, leukocyte recruitment, and acute-phase responses together rather than as isolated events. This makes the pathway useful for interpreting how early immune signals organize systemic and local inflammation.
IL-1 research extends beyond host defense because persistent or misdirected inflammatory signaling is relevant to autoimmune disease and chronic disorders such as rheumatoid arthritis. Investigators use this pathway to relate cytokine signaling to disease-associated inflammation. The connection also supports research into interventions designed to reduce IL-1-driven inflammatory activity in clinical settings.
Therapeutic strategies can target the IL-1 system at the receptor or elsewhere in its signaling pathway. IL-1 receptor antagonists provide an example of blocking receptor-mediated effects, while other pathway-targeting therapies illustrate alternative points of modulation. These approaches demonstrate how mechanistic understanding can be translated into attempts to control inflammation in disease without treating the pathway as a single, unregulated process.